Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

XOMA Corporation (XOMA)

27.22   2.21 (8.84%) 02-14 16:00
Open: 25.17 Pre. Close: 25.01
High: 27.32 Low: 25.08
Volume: 52,021 Market Cap: 266M
XOMA Corp is a biotechnology company. It discovers and develops human and humanized monoclonal antibody-based therapeutics.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 27.345 - 27.478 27.478 - 27.592
Low: 24.782 - 24.926 24.926 - 25.05
Close: 26.989 - 27.228 27.228 - 27.434

Technical analysis

as of: 2020-02-14 4:33:55 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 31.91     One year: 37.27
Support: Support1: 24.16    Support2: 22.20
Resistance: Resistance1: 27.32    Resistance2: 31.91
Pivot: 24.44
Moving Average: MA(5): 25.47     MA(20): 24.33
MA(100): 22.95     MA(250): 18.78
MACD: MACD(12,26): 0.25     Signal(9): -0.06
Stochastic oscillator: %K(14,3): 84.90     %D(3): 79.46
RSI: RSI(14): 66.25
52-week: High: 28.85  Low: 11.58  Change(%): 91.6
Average Vol(K): 3-Month: 7687  10-Days: 5529

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
XOMA has closed above the upper band by 10.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 6.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan plc (NYSE: AGN )(announced publication of Phase 3 study results of migraine drug candidate) Agenus Inc (NASDAQ: AGEN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS )(announced a collaboration agreement with Idorsia Pharma for developing a drug-device combo for heart attack) Ardelyx Inc (NASDAQ: ARDX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) CNS Pharmaceuticals Inc (NASDAQ: CNSP )(IPOed Nov. 8) Crispr Therapeutics AG (NASDAQ: CRSP )( announced positive Phase 1/2 results for gene-editing investigational therapy) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Galera Therapeutics Inc (NASDAQ: GRTX )(IPOed Nov.

The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) Crispr Therapeutics AG (NASDAQ: CRSP ) DexCom, Inc. (NASDAQ: DXCM Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) )(announced a partnership with Novo Nordisk A/S (NYSE: NVO ) for developing RNAi therapies) Frequency Therapeutics Inc (NASDAQ: FREQ )(reacted to its third-quarter results) GENMAB A/S/S ADR (NASDAQ: GMAB ) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Karuna Therapeutics Inc (NASDAQ: KRTX )( announced positive results for its mid-stage schizophrenia drug) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) Krystal Biotech Inc (NASDAQ: KRYS ) The Medicines Company (NASDAQ: MDCO )(announced full results of its ORION-9 Phase 3 study of inclisiran at the American Heart Association 2019 annual meeting) Medtronic PLC (NYSE: MDT ) Neurocrine Biosciences, Inc.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 8.76
Shares Float (M) 5.84
% Held by Insiders 6.94
% Held by Institutions 52.60
Shares Short (K) 410
Shares Short P. Month (K)

Stock Financials

EPS -0.190
Book Value (p.s.) 2.950
PEG Ratio -5.58
Profit Margin -3.43
Operating Margin -14.07
Return on Assets (ttm) -2.6
Return on Equity (ttm) -5.0
Qtrly Rev. Growth 888.3
Gross Profit (p.s.) 0.413
Sales Per Share
EBITDA (p.s.) -0.313
Qtrly Earnings Growth
Operating Cash Flow (M) 1.15
Levered Free Cash Flow (M) -20.79

Stock Valuations

P/E -143.26
P/E Growth Ratio 0.09
P/BV 9.23
P/S 11.99
P/CF 207.35

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2016-10-17
Last Split Ratio 0.05
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.